Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9628092 | 0.85 | CYP2C19 (0.47) | MAPTTDP1L3MBTL1MAPK1LMNA | |
| SCHEMBL17912876 | 0.84 | LMNA (0.46) | HTTLMNAPKMCASP3CASP7 | |
| SCHEMBL19612242 | 0.83 | MRGPRX4 (0.53) | MAPTSMN1; SMN2MRGPRX4RXRAHDAC6 | |
| SCHEMBL8756078 | 0.82 | MAPT (0.56) | MAPTTDP1L3MBTL1MAPK1HTT | |
| SCHEMBL19612318 | 0.82 | MAPT (0.51) | MAPTTDP1L3MBTL1MAPK1HTT | |
| SCHEMBL17912830 | 0.81 | HTT (0.53) | MAPTL3MBTL1HTTLMNAPKM | |
| SCHEMBL17912858 | 0.81 | ACLY (0.47) | MAPTTDP1L3MBTL1MAPK1LMNA | |
| SCHEMBL11727739 | 0.79 | MAPK1 (0.49) | MAPTTDP1L3MBTL1MAPK1HTT | |
| SCHEMBL10823520 | 0.79 | ELANE (0.46) | — | |
| SCHEMBL15869751 | 0.79 | MAPT (0.51) | MAPTTDP1L3MBTL1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4056619-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1977-11-01 | — | — | US | claimed |
| US-20170336728-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | CANON KABUSHIKI KAISHA (JP) | 2017-11-23 | — | — | US | disclosed |
| EP-3242897-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | C/o Canon Kabushiki Kaisha (JP) | 2017-11-15 | — | — | EP | disclosed |
| CN-107108774-A | Ultra-violet solidified fluid composition, the uv-curing type ink jet ink using it, ultraviolet hardening wet type electrophotographic liquid developer, ultraviolet hardening electrostatic inkjet ink and image forming method | 佳能株式会社 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016111380-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | CANON KABUSHIKI KAISHA (JP) | 2016-07-14 | — | — | WO | disclosed |
| US-6358515-B2 | ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-20010008893-A1 | HYDROQUINONE DERIVATIVES | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | disclosed |
| EP-0972766-A1 | HYDROQUINONE DERIVATIVES | Senju Pharmaceutical Co., Ltd. (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-4060558-A | MULTISTAGE FROM BENZYL HALIDE ALKYLATION OF 1-ACYLATED-1,4-NAPHTHOQUINOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1977-11-29 | — | — | US | disclosed |
| US-3948958-A | Process for making 3-prenylated menaquinones and ether intermediates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008893-A1 | HYDROQUINONE DERIVATIVES | REN, AGTR1, AGTR2 | MAPT 4729/4885TDP1 3374/4885L3MBTL1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.